
BioHarvest Sciences Inc. (OTCPK:CNVCF) (CSE:BHSC) (FSE:8MV) revealed Q2 2022 sales orders of its flagship VINIA product reached a record high of $947,000, representing 99% growth compared to the same quarter of last year and 24% growth compared to Q1 2022.
BioHarvest also had a strong quarter in R&D execution, highlighted by a May 12th announcement unveiling the profile of its cannabis biomass composition produced in large-scale industrial bioreactors. BioHarvest also applied for a cannabis production license in Israel. This quarter also saw the transition to the new 20Tons/year VINIA facility in Yavneh, Israel which will enable the further scaling of the VINIA business in the US in H2, 2022 and will deliver significant cost reductions over the next 12 months.